HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes

Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis

(2020) Amanda N. Fader et al.   CLINICAL CANCER RESEARCH

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

(2020) Alicia León-Castillo et al.   JOURNAL OF CLINICAL ONCOLOGY

Attenuation of p53 mutant as an approach for treatment Her2-positive cancer

(2020) Olga Fedorova et al.   Cell Death Discovery

Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series

(2018) S Kommoss et al.   ANNALS OF ONCOLOGY

Mutant p53 gain of function induces HER2 over-expression in cancer cells

(2018) A. A. Román-Rosales et al.   BMC CANCER

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

(2018) Amanda N. Fader et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

(2018) Stephanie M de Boer et al.   LANCET ONCOLOGY

HER2Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma

(2016) Angela N. Bartley et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma

(2016) MARTIN KOSKAS et al.   ANTICANCER RESEARCH

Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

(2016) Ellen Stelloo et al.   CLINICAL CANCER RESEARCH

Just how accurate are the major risk stratification systems for early-stage endometrial cancer?

(2015) S Bendifallah et al.   BRITISH JOURNAL OF CANCER

Erratum: PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

(2015) Jonathan D Black et al.   BRITISH JOURNAL OF CANCER

A clinically applicable molecular-based classification for endometrial cancers

(2015) A Talhouk et al.   BRITISH JOURNAL OF CANCER

The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer

(2015) E. J. Diver et al.   ONCOLOGIST

HER2/neuin Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges

(2014) Natalia Buza et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

PIK3CAMutations Are Associated With Lower Rates of Pathologic Complete Response to Anti–Human Epidermal Growth Factor Receptor 2 (HER2) Therapy in Primary HER2-Overexpressing Breast Cancer

(2014) Sibylle Loibl et al.   JOURNAL OF CLINICAL ONCOLOGY

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

(2014) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

A gain-of-function mutant p53–HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress

(2014) D Li et al.   Cell Death & Disease

Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma

(2013) C. Blake Gilks et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Marked heterogeneity ofHER2/NEUgene amplification in endometrial serous carcinoma

(2013) Natalia Buza et al.   GENES CHROMOSOMES & CANCER

Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice

(2013) Natalia Buza et al.   MODERN PATHOLOGY

Integrated genomic characterization of endometrial carcinoma

(2013) Gad Getz et al.   NATURE

ClinVar: public archive of relationships among sequence variation and human phenotype

(2013) Melissa J. Landrum et al.   NUCLEIC ACIDS RESEARCH

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

A method and server for predicting damaging missense mutations

(2010) Ivan A Adzhubei et al.   NATURE METHODS

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

(2010) Josef Rüschoff et al.   VIRCHOWS ARCHIV

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study

(2009) Gini F. Fleming et al.   GYNECOLOGIC ONCOLOGY

Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

(2009) Prateek Kumar et al.   Nature Protocols

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

(2008) C. Gravalos et al.   ANNALS OF ONCOLOGY

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer

(2008) G E Konecny et al.   BRITISH JOURNAL OF CANCER

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY